The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the ...

BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...